Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


INFOGRAPHIC: Pricing and reimbursement in Poland – problems and progress

This article was originally published in Scrip

Executive Summary

The introduction of the Reimbursement Act in Poland in 2012 brought a number of significant changes in the Polish pharmaceutical market place. Initially trends following the new Act were received negatively by the industry. However, two years on, opportunity is rising in the region both for generic players due to the country's universal insurance coverage, and for innovative new medicines following the adoption of Risk Sharing Agreements and bids by government to speed up appraisal processes.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts